| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| MousePheno | enlarged stomach | 8.67e-06 | 33 | 56 | 4 | MP:0003883 | |
| Domain | - | IBTK ANK2 ANKRD20A4P BARD1 ANKRD28 ANKRD20A2P ANKRD20A3P BANK1 ANKRD20A1 | 2.13e-07 | 248 | 66 | 9 | 1.25.40.20 |
| Domain | ANK_REPEAT | IBTK ANK2 ANKRD20A4P BARD1 ANKRD28 ANKRD20A2P ANKRD20A3P BANK1 ANKRD20A1 | 2.52e-07 | 253 | 66 | 9 | PS50088 |
| Domain | Ankyrin_rpt-contain_dom | IBTK ANK2 ANKRD20A4P BARD1 ANKRD28 ANKRD20A2P ANKRD20A3P BANK1 ANKRD20A1 | 2.60e-07 | 254 | 66 | 9 | IPR020683 |
| Domain | ANK_REP_REGION | IBTK ANK2 ANKRD20A4P BARD1 ANKRD28 ANKRD20A2P ANKRD20A3P BANK1 ANKRD20A1 | 2.60e-07 | 254 | 66 | 9 | PS50297 |
| Domain | Ankyrin_rpt | IBTK ANK2 ANKRD20A4P BARD1 ANKRD28 ANKRD20A2P ANKRD20A3P BANK1 ANKRD20A1 | 3.38e-07 | 262 | 66 | 9 | IPR002110 |
| Domain | Ank_2 | IBTK ANK2 ANKRD20A4P BARD1 ANKRD28 ANKRD20A2P ANKRD20A3P ANKRD20A1 | 8.76e-07 | 215 | 66 | 8 | PF12796 |
| Domain | Ank | IBTK ANK2 ANKRD20A4P BARD1 ANKRD28 ANKRD20A2P ANKRD20A3P ANKRD20A1 | 1.36e-06 | 228 | 66 | 8 | PF00023 |
| Domain | ANK | IBTK ANK2 ANKRD20A4P BARD1 ANKRD28 ANKRD20A2P ANKRD20A3P ANKRD20A1 | 2.79e-06 | 251 | 66 | 8 | SM00248 |
| Domain | uDENN | 1.09e-03 | 14 | 66 | 2 | SM00800 | |
| Domain | uDENN | 1.25e-03 | 15 | 66 | 2 | PF03456 | |
| Domain | UDENN | 1.43e-03 | 16 | 66 | 2 | PS50946 | |
| Domain | DDENN | 1.43e-03 | 16 | 66 | 2 | PS50947 | |
| Domain | DENN | 1.43e-03 | 16 | 66 | 2 | SM00799 | |
| Domain | dDENN | 1.43e-03 | 16 | 66 | 2 | SM00801 | |
| Domain | DENN | 1.43e-03 | 16 | 66 | 2 | PF02141 | |
| Domain | dDENN_dom | 1.43e-03 | 16 | 66 | 2 | IPR005112 | |
| Domain | uDENN_dom | 1.43e-03 | 16 | 66 | 2 | IPR005113 | |
| Domain | dDENN | 1.43e-03 | 16 | 66 | 2 | PF03455 | |
| Domain | DENN | 1.43e-03 | 16 | 66 | 2 | PS50211 | |
| Domain | DENN_dom | 1.43e-03 | 16 | 66 | 2 | IPR001194 | |
| Domain | Gal_mutarotase_SF_dom | 1.62e-03 | 17 | 66 | 2 | IPR011013 | |
| Domain | DnaJ_domain_CS | 4.08e-03 | 27 | 66 | 2 | IPR018253 | |
| Domain | ABC_TM1F | 4.38e-03 | 28 | 66 | 2 | PS50929 | |
| Domain | ABC1_TM_dom | 4.38e-03 | 28 | 66 | 2 | IPR011527 | |
| Pubmed | Expression of testicular germ cell genes identified by differential display analysis. | 1.05e-09 | 8 | 70 | 4 | 12634303 | |
| Pubmed | IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. | 5.88e-06 | 58 | 70 | 4 | 21642987 | |
| Pubmed | 1.20e-05 | 3 | 70 | 2 | 32636307 | ||
| Pubmed | TBX1 is required for normal stria vascularis and semicircular canal development. | 3.37e-05 | 31 | 70 | 3 | 31550482 | |
| Pubmed | Structural diversity and evolution of human receptor-like protein tyrosine phosphatases. | 5.96e-05 | 6 | 70 | 2 | 2170109 | |
| Pubmed | Receptor protein tyrosine phosphatases are novel components of a polycystin complex. | 5.96e-05 | 6 | 70 | 2 | 21126580 | |
| Pubmed | The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery. | VRK2 ERGIC3 ANAPC1 DDR2 C6orf120 ABCB8 ZNF629 ZMYM4 FAM241A HNRNPU | 1.42e-04 | 1203 | 70 | 10 | 29180619 |
| Pubmed | 1.99e-04 | 418 | 70 | 6 | 34709266 | ||
| Pubmed | 2.17e-04 | 11 | 70 | 2 | 20493910 | ||
| Pubmed | 2.98e-04 | 64 | 70 | 3 | 22261194 | ||
| Pubmed | 3.34e-04 | 650 | 70 | 7 | 38777146 | ||
| Pubmed | 3.58e-04 | 14 | 70 | 2 | 17382312 | ||
| Pubmed | BGL3 lncRNA mediates retention of the BRCA1/BARD1 complex at DNA damage sites. | 4.39e-04 | 73 | 70 | 3 | 32347575 | |
| Pubmed | 4.60e-04 | 686 | 70 | 7 | 29987050 | ||
| Pubmed | Protein tyrosine phosphatases expression during development of mouse superior colliculus. | 5.33e-04 | 17 | 70 | 2 | 19727691 | |
| Pubmed | 5.33e-04 | 17 | 70 | 2 | 10931824 | ||
| Pubmed | 5.33e-04 | 17 | 70 | 2 | 19759019 | ||
| Pubmed | Mapping of five subtype genes for muscarinic acetylcholine receptor to mouse chromosomes. | 5.33e-04 | 17 | 70 | 2 | 10549128 | |
| Pubmed | G3BP1 DNAJA2 ZNF629 WDR83 ANKRD28 RELB PAX9 MORC4 USP27X ZMYM4 | 5.59e-04 | 1429 | 70 | 10 | 35140242 | |
| Pubmed | 5.98e-04 | 18 | 70 | 2 | 1358795 | ||
| Pubmed | A Degradation Motif in STAU1 Defines a Novel Family of Proteins Involved in Inflammation. | 6.33e-04 | 724 | 70 | 7 | 36232890 | |
| Pubmed | LCP1 preferentially binds clasped αMβ2 integrin and attenuates leukocyte adhesion under flow. | 6.57e-04 | 344 | 70 | 5 | 30333137 | |
| Pubmed | 6.95e-04 | 963 | 70 | 8 | 28671696 | ||
| Pubmed | Compartmentalization of the SUMO/RNF4 pathway by SLX4 drives DNA repair. | 7.77e-04 | 357 | 70 | 5 | 37059091 | |
| Pubmed | 8.09e-04 | 90 | 70 | 3 | 23151878 | ||
| Pubmed | 8.24e-04 | 547 | 70 | 6 | 37267103 | ||
| Pubmed | 1.01e-03 | 97 | 70 | 3 | 25071155 | ||
| Pubmed | 1.07e-03 | 1285 | 70 | 9 | 35914814 | ||
| Pubmed | Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability. | 1.19e-03 | 588 | 70 | 6 | 38580884 | |
| Pubmed | 1.23e-03 | 104 | 70 | 3 | 9205841 | ||
| Pubmed | Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. | 1.30e-03 | 1061 | 70 | 8 | 33845483 | |
| Pubmed | 1.33e-03 | 107 | 70 | 3 | 30995489 | ||
| Pubmed | 1.36e-03 | 27 | 70 | 2 | 24586749 | ||
| Pubmed | The cell proliferation antigen Ki-67 organises heterochromatin. | 1.43e-03 | 410 | 70 | 5 | 26949251 | |
| Pubmed | 1.46e-03 | 28 | 70 | 2 | 38492217 | ||
| Pubmed | 1.57e-03 | 29 | 70 | 2 | 21532586 | ||
| Pubmed | The human cytoplasmic dynein interactome reveals novel activators of motility. | 1.63e-03 | 853 | 70 | 7 | 28718761 | |
| Pubmed | Identifying and quantifying in vivo methylation sites by heavy methyl SILAC. | 1.67e-03 | 30 | 70 | 2 | 15782174 | |
| Pubmed | 1.68e-03 | 116 | 70 | 3 | 21549307 | ||
| Pubmed | HERC2 Facilitates BLM and WRN Helicase Complex Interaction with RPA to Suppress G-Quadruplex DNA. | 1.79e-03 | 31 | 70 | 2 | 30279242 | |
| Pubmed | BTB-ZF factors recruit the E3 ligase cullin 3 to regulate lymphoid effector programs. | 1.79e-03 | 31 | 70 | 2 | 23086144 | |
| Interaction | ANKRD20A4P interactions | 7.97e-07 | 6 | 70 | 3 | int:ANKRD20A4P | |
| Interaction | ANKRD20A2P interactions | 1.39e-06 | 7 | 70 | 3 | int:ANKRD20A2P | |
| Interaction | ANKRD20A1 interactions | 6.49e-06 | 11 | 70 | 3 | int:ANKRD20A1 | |
| Cytoband | 5q33.1 | 7.27e-04 | 26 | 70 | 2 | 5q33.1 | |
| Cytoband | 9p12 | 9.06e-04 | 29 | 70 | 2 | 9p12 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr1p34 | 1.08e-03 | 294 | 70 | 4 | chr1p34 | |
| Cytoband | 1p33 | 1.32e-03 | 35 | 70 | 2 | 1p33 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr9q13 | 3.35e-03 | 56 | 70 | 2 | chr9q13 | |
| GeneFamily | Ankyrin repeat domain containing | IBTK ANK2 ANKRD20A4P BARD1 ANKRD28 ANKRD20A2P ANKRD20A3P BANK1 ANKRD20A1 | 2.65e-08 | 242 | 52 | 9 | 403 |
| GeneFamily | Protein tyrosine phosphatases, receptor type | 1.65e-03 | 21 | 52 | 2 | 813 | |
| GeneFamily | Guanylate cyclase receptors|DENN/MADD domain containing | 2.33e-03 | 25 | 52 | 2 | 504 | |
| GeneFamily | Tetratricopeptide repeat domain containing|Bardet-Biedl syndrome associated|BBSome | 4.42e-03 | 115 | 52 | 3 | 769 | |
| GeneFamily | DNAJ (HSP40) heat shock proteins|C2 tensin-type domain containing | 8.75e-03 | 49 | 52 | 2 | 584 | |
| GeneFamily | Fibronectin type III domain containing | 1.09e-02 | 160 | 52 | 3 | 555 | |
| GeneFamily | Ubiquitin specific peptidases | 1.13e-02 | 56 | 52 | 2 | 366 | |
| Coexpression | WIERENGA_STAT5A_TARGETS_DN | 1.20e-05 | 193 | 69 | 6 | M2213 | |
| ToppCell | Control-Myeloid-cDC1|Myeloid / Disease state, Lineage and Cell class | DENND1B ANKRD20A4P ANKRD20A2P ANKRD20A3P ANKRD20A8P ANKRD20A1 | 4.55e-07 | 184 | 70 | 6 | c6affa0b12510363258f65e46bf2d47bf4a8e75f |
| ToppCell | COPD-Myeloid-cDC1|World / Disease state, Lineage and Cell class | DENND1B ANKRD20A4P ANKRD20A2P ANKRD20A3P ANKRD20A8P ANKRD20A1 | 4.55e-07 | 184 | 70 | 6 | 42d7ce104cd7bcb83fbbbd0e7d3267ad07edfa94 |
| ToppCell | IPF-Myeloid-cDC1|World / Disease state, Lineage and Cell class | DENND1B ANKRD20A4P ANKRD20A2P ANKRD20A3P ANKRD20A8P ANKRD20A1 | 4.85e-07 | 186 | 70 | 6 | 962c2dada19185628ead77c32fcb07fa95114247 |
| ToppCell | Control-Myeloid-cDC1|Control / Disease state, Lineage and Cell class | DENND1B ANKRD20A4P ANKRD20A2P ANKRD20A3P ANKRD20A8P ANKRD20A1 | 4.85e-07 | 186 | 70 | 6 | b05c394aa3573ba855abc3066739ca193883b0c3 |
| ToppCell | IPF-Myeloid-cDC1|IPF / Disease state, Lineage and Cell class | DENND1B ANKRD20A4P ANKRD20A2P ANKRD20A3P ANKRD20A8P ANKRD20A1 | 5.16e-07 | 188 | 70 | 6 | 2331a2bae1383820d598e93aa86c75b101069bac |
| ToppCell | COPD-Myeloid-cDC1|Myeloid / Disease state, Lineage and Cell class | DENND1B ANKRD20A4P ANKRD20A2P ANKRD20A3P ANKRD20A8P ANKRD20A1 | 5.66e-07 | 191 | 70 | 6 | 3480e6d27dd4291765bbbb2acdb6a2e4f02c8085 |
| ToppCell | COPD-Myeloid-cDC1|COPD / Disease state, Lineage and Cell class | DENND1B ANKRD20A4P ANKRD20A2P ANKRD20A3P ANKRD20A8P ANKRD20A1 | 5.84e-07 | 192 | 70 | 6 | bd3d00b094d92463b06023361a71240851a542b8 |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.78e-07 | 197 | 70 | 6 | 94a9603cbd3516fbcce871909693b88f20d41713 | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 7.19e-07 | 199 | 70 | 6 | 30d3e8c0681ec11f86dd38c5f48d21187a1b4f90 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 7.41e-07 | 200 | 70 | 6 | 9b0916d8d07ac2bf1739f7be5296bf77ffee6094 | |
| ToppCell | LPS_only-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_only / Treatment groups by lineage, cell group, cell type | 7.41e-07 | 200 | 70 | 6 | a7ef7022b8efcaedb7319b0b43d8c4e99d788fe2 | |
| ToppCell | P15-Mesenchymal-mesenchymal_fibroblast-mesenchymal_progenitor_cell|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 7.20e-06 | 170 | 70 | 5 | ba4ba66b624089ed50a9083176386c7941b4c7a3 | |
| ToppCell | 356C-Myeloid-Macrophage-FABP4+_Macrophage_3|Myeloid / Donor, Lineage, Cell class and subclass (all cells) | 8.76e-06 | 177 | 70 | 5 | 3d955ea938a1d2fb1b6d68d4997fd454bd632dfc | |
| ToppCell | 5'-Adult-Distal_Rectal-Mesenchymal-fibroblastic-mLN_Stroma_(FMO2+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.09e-05 | 185 | 70 | 5 | 9faa35ceb89ccd2979072286f063687c9f846ce3 | |
| ToppCell | Control-Myeloid-cDC1|World / Disease state, Lineage and Cell class | 1.11e-05 | 186 | 70 | 5 | 3de803dee3ef10eb85a2b47d3f93385214e5b0ff | |
| ToppCell | Control-Endothelial-VE_Peribronchial|Endothelial / Disease state, Lineage and Cell class | 1.14e-05 | 187 | 70 | 5 | 5429ae85942b8ec3895cceb63c663de3c24ca064 | |
| ToppCell | IPF-Myeloid-cDC1|Myeloid / Disease state, Lineage and Cell class | 1.17e-05 | 188 | 70 | 5 | 47bb6caf84f70a1cda7d09803afdfd5182772e66 | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.20e-05 | 189 | 70 | 5 | 2a22b9fae70afb3dab8476f9c00e48a4df756410 | |
| ToppCell | Control-Fibroblasts|Control / group, cell type (main and fine annotations) | 1.23e-05 | 190 | 70 | 5 | 3a42a9b98d954685d38a741f44545898d0e3e9ce | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.27e-05 | 191 | 70 | 5 | b13229bb7f3713a392271aaf5dbae3edd1b9fe5a | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.36e-05 | 194 | 70 | 5 | 89b706af2b25991fc2707eb24f49ba6ff3ae01f7 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 1.47e-05 | 197 | 70 | 5 | fdb92985f7df0c280b87d3e43c2394e70786a2c7 | |
| ToppCell | COVID-19_Severe|World / Disease group, lineage and cell class | 1.47e-05 | 197 | 70 | 5 | f0824f98269bdcd8463873beaf222df8f0caa468 | |
| ToppCell | PBMC-Severe|PBMC / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.47e-05 | 197 | 70 | 5 | af10b5e6e959e2ced01ad066f906941bc4194cc3 | |
| ToppCell | PBMC-Severe|PBMC / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.47e-05 | 197 | 70 | 5 | 3ff23b86d310ace388d2efb3ee73dd47c46f363e | |
| ToppCell | mLN-(5)_Dendritic_cell-(53)_Lymphoid_DC|mLN / shred on region, Cell_type, and subtype | 1.51e-05 | 198 | 70 | 5 | da84c76afe835aeee39da04b63c03549218b5d91 | |
| ToppCell | COVID-19-lung-Fibroblast|lung / Disease (COVID-19 only), tissue and cell type | 1.51e-05 | 198 | 70 | 5 | df3de77216f5c5d6141ec44d01c56b942f611838 | |
| ToppCell | mLN-Dendritic_cell-Lymphoid_DC|mLN / Region, Cell class and subclass | 1.51e-05 | 198 | 70 | 5 | 3965a9f1e8a51a196e5349aaca5fa5ed1cd8ee92 | |
| ToppCell | LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 1.54e-05 | 199 | 70 | 5 | a7dd94b172c973a131a6792f8ccd9bfe44d984ac | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.54e-05 | 199 | 70 | 5 | e1849505b92820a219c5a2c35492bdd55579fb48 | |
| ToppCell | LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 1.54e-05 | 199 | 70 | 5 | 8b86c69aaf60feff53aa782559cfece7342a23de | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 1.58e-05 | 200 | 70 | 5 | b79628fd1386aa9a3b0e9fa81def0bc100c3c073 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 1.58e-05 | 200 | 70 | 5 | 50ca6550998e461ef26dd670351060bd940765a8 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Diff_MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 1.58e-05 | 200 | 70 | 5 | 3bdba9612cd7c612b76aa9abecc4a6529aabfc1c | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.58e-05 | 200 | 70 | 5 | 44a68bacdb3d5bf563bd35952176995850933a81 | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.58e-05 | 200 | 70 | 5 | dc61016c61729f69649cfb21f6264e685ce83dea | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|Control_saline / Treatment groups by lineage, cell group, cell type | 1.58e-05 | 200 | 70 | 5 | bd8cf33502adea320e91ca2af14e1911d88ad374 | |
| ToppCell | IIH-CD4-CD8_1|IIH / Condition, Cell_class and T cell subcluster | 8.04e-05 | 145 | 70 | 4 | 296b6b0eea3233d76742ea35252b2f54d4c27ab6 | |
| ToppCell | COVID-19-Heart-Adipocyte|COVID-19 / Disease (COVID-19 only), tissue and cell type | 9.90e-05 | 153 | 70 | 4 | 93958bd9c951222ba5b740d1cb83fd5d78a10e1e | |
| ToppCell | LV-11._Adipocyte|World / Chamber and Cluster_Paper | 1.36e-04 | 166 | 70 | 4 | 7e5852891714465c6228c9f955fd511ec79d0e02 | |
| ToppCell | Adult-Mesenchymal-chondrocyte-D175|Adult / Lineage, Cell type, age group and donor | 1.42e-04 | 168 | 70 | 4 | 14071b961c9bdb54a8259b12a88237b802cbde36 | |
| ToppCell | COVID-19-Heart-Adipocyte|Heart / Disease (COVID-19 only), tissue and cell type | 1.45e-04 | 169 | 70 | 4 | bd39f85b48207955f80ca120a11e15a0124117b9 | |
| ToppCell | 390C-Lymphocytic-NK_cells-NK_cell_C|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 1.49e-04 | 170 | 70 | 4 | 81341bf4fe090af70b2091b6b2579ed08d76e22d | |
| ToppCell | 3'-Broncho-tracheal-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.55e-04 | 172 | 70 | 4 | e37c0b5b547a7345179ab258dd2141fec7064c17 | |
| ToppCell | LV-11._Adipocyte|LV / Chamber and Cluster_Paper | 1.59e-04 | 173 | 70 | 4 | c2d3fcb3de71015d03d14c63450853d2b03ffa71 | |
| ToppCell | Basal_cells-Cryobiopsy_01|World / lung cells shred on cell class, cell subclass, sample id | 1.62e-04 | 174 | 70 | 4 | a0060be3940043015dcc49a5157de5541aed24a1 | |
| ToppCell | metastatic_Brain-Myeloid_cells-CD141+_DCs|Myeloid_cells / Location, Cell class and cell subclass | 1.62e-04 | 174 | 70 | 4 | 5ec8a48a390379d6c422120dce46437a77da67cc | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT_L6_FEZF2-Exc_L5-6_FEZF2_ANKRD20A1|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.62e-04 | 174 | 70 | 4 | 99eb5e1aee136c7039e23b68a43a0fa3d775859f | |
| ToppCell | 10x5'-blood-Lymphocytic_T_CD4-Tfh|blood / Manually curated celltypes from each tissue | 1.66e-04 | 175 | 70 | 4 | d7e24ac683ff36f7ce3d1151353d3d4a6f2b63bf | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.85e-04 | 180 | 70 | 4 | 08ae0f5d95c45feba68ad99788f7af7ff4c979af | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Medullary_Thick_Ascending_Limb_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.85e-04 | 180 | 70 | 4 | 9e09b3dfe344b5d50520711513d389865d73a861 | |
| ToppCell | Control-Epithelial_cells-AT2|Control / group, cell type (main and fine annotations) | 1.85e-04 | 180 | 70 | 4 | 198b19e7910b4a8cc7e820c525ab357c7f99f578 | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.85e-04 | 180 | 70 | 4 | 9b1de1b4711adbf9a423f4d2d08f3f4c78f1f8f4 | |
| ToppCell | droplet-Liver-Npc-21m-Epithelial-nan|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.91e-04 | 71 | 70 | 3 | cf4c8715c2bd77fc86e45cc01bcc7aa6044e091d | |
| ToppCell | facs-Liver-Hepatocytes-24m-Epithelial|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.93e-04 | 182 | 70 | 4 | 770ce9f3f4538d0181a0181543841bc964c68274 | |
| ToppCell | facs-Liver-Hepatocytes-24m-Epithelial-nan|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.93e-04 | 182 | 70 | 4 | 77ab860e2add49dad0c1ffbfc64278ad499dfbd5 | |
| ToppCell | facs-Liver-Hepatocytes-24m-Epithelial-hepatocyte|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.93e-04 | 182 | 70 | 4 | 4921c7d5687cc79f896b39753bb621d7e3d2972f | |
| ToppCell | COPD-Epithelial-ATII|World / Disease state, Lineage and Cell class | 1.97e-04 | 183 | 70 | 4 | 8e9aab4eeec2e282c2cab9bfca6dbf40d660c7b9 | |
| ToppCell | facs-Liver-Hepatocytes-24m|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.97e-04 | 183 | 70 | 4 | d0721c6aa426953a520d40e976b6e65aa7ca65e8 | |
| ToppCell | Parenchymal-10x3prime_v2-Immune_Lymphocytic-T-T_CD8-CD8_TRM|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 2.01e-04 | 184 | 70 | 4 | 17ffa0e890960c00a3b5fa33d48caba66c61dbb0 | |
| ToppCell | normal-na-Lymphocytic-lymphocyte-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 2.01e-04 | 184 | 70 | 4 | 2c286712428662bc4589dc5ac4011bf7ed403cb5 | |
| ToppCell | COVID-19-Fibroblasts-Adventitial_FB|COVID-19 / group, cell type (main and fine annotations) | 2.05e-04 | 185 | 70 | 4 | a5aebf2b9b05b550d021272731d68af9a6b1229d | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.10e-04 | 186 | 70 | 4 | 5473283fb95cee556b1f6934cf72169b676b5bcc | |
| ToppCell | droplet-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l20-25|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 2.14e-04 | 187 | 70 | 4 | 0d4b7da81036c2aa678654b9fe49c939d08fcd9b | |
| ToppCell | Control-Fibroblasts-Adventitial_FB|Control / group, cell type (main and fine annotations) | 2.18e-04 | 188 | 70 | 4 | 706a26c372add839d947749f0521a0e1f5c9b0ec | |
| ToppCell | COPD-Epithelial-ATII|COPD / Disease state, Lineage and Cell class | 2.18e-04 | 188 | 70 | 4 | eb6d79d733b53f64ca615bb777c64ed456866549 | |
| ToppCell | 3'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_CCL3+-Alveolar_macrophage_CCL3+_L.1.0.2.4|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.23e-04 | 189 | 70 | 4 | a59025e82fabd9d60e2438dee85b2644478cc7c8 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.23e-04 | 189 | 70 | 4 | a153b83314cf52808f685296cff8c95af3f4983d | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.27e-04 | 190 | 70 | 4 | 1121eb607a984c59fbffe7220837fc178745aa55 | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_2_cell-D175|Adult / Lineage, Cell type, age group and donor | 2.27e-04 | 190 | 70 | 4 | 7dcca3469f3a3b70db0420cb94f7765f39492f06 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.27e-04 | 190 | 70 | 4 | 048b581e3f7ea9fc2f87c0532974bba85c7292c2 | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.27e-04 | 190 | 70 | 4 | 45df8fee00f8949937863159d7aa042e72748d9b | |
| ToppCell | PND10|World / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.27e-04 | 190 | 70 | 4 | d67e2814047c8df2ae4b7bc8be9539f5df6ecef2 | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_2_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 2.27e-04 | 190 | 70 | 4 | 0fea33f2dc1efa23aaa2da1c318482a52a313ff1 | |
| ToppCell | PND07-28-samps-Mesenchymal-Myofibroblast|PND07-28-samps / Age Group, Lineage, Cell class and subclass | 2.32e-04 | 191 | 70 | 4 | 9bbafdf316c1fa3a9f1ee30d41dd7158b5c97279 | |
| ToppCell | facs-Aorta-Heart-3m-Mesenchymal-fibroblast|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.32e-04 | 191 | 70 | 4 | 9214655dca96d766737c9f30b624d7fe7050342e | |
| ToppCell | Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.32e-04 | 191 | 70 | 4 | a0332a4ef629510fb313ec119195c44a3f704a80 | |
| ToppCell | 10x5'v1-week_14-16-Hematopoietic-MK|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 2.32e-04 | 191 | 70 | 4 | 7edc22e7e70697fb22690699efb352577162709b | |
| ToppCell | droplet-Limb_Muscle-Pre-Sort-18m-Mesenchymal-mesenchymal_stem_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.32e-04 | 191 | 70 | 4 | 1b26056df078674f37a6c06f6256b30cfcec21a7 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.36e-04 | 192 | 70 | 4 | 6f4ef24dab544681304b7f8a9dc073e7edaa4cf5 | |
| ToppCell | facs-Heart-LV-3m-Mesenchymal-fibroblast_of_cardiac_tissue|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.36e-04 | 192 | 70 | 4 | 671d4e1eee5aba03c43dbc98f4b51ce42b3df5d5 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.36e-04 | 192 | 70 | 4 | dcd924d6eb67d33ee9f5d3e8ab6e1d4283d6b708 | |
| ToppCell | LPS_only-Stromal_mesenchymal|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.36e-04 | 192 | 70 | 4 | 162d8b5858d150ecbbd1c9bf2b19c6c9cd50a158 | |
| ToppCell | Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.36e-04 | 192 | 70 | 4 | cc9911e182a289779a2612bc213daae5607689e7 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.36e-04 | 192 | 70 | 4 | 3d0cb19f037f604253d7d728689aeaa94251e92b | |
| ToppCell | facs-Heart-LV-3m-Mesenchymal-fibroblast_of_cardiac_tissue|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.36e-04 | 192 | 70 | 4 | 840a34c1b82d218be999ab5e1bcafd6370d7a4b1 | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Medullary_Thick_Ascending_Limb_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.36e-04 | 192 | 70 | 4 | ee27d27e3d269764dbe8711d0b37ff9331a298a9 | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.36e-04 | 192 | 70 | 4 | deeecd26972241846b4cb998edf0c7a87ff0c4df | |
| ToppCell | nucseq-Epithelial-Epithelial_Alveolar-AT2-AT2|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.41e-04 | 193 | 70 | 4 | fd4d3c0d7caf8a2fff5b3d901fc28d19a8163cdf | |
| ToppCell | NS-critical-d_0-4-Lymphoid-NK|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 2.41e-04 | 193 | 70 | 4 | 1b29525c5936d1b779253b8c20f059fa091c6127 | |
| ToppCell | droplet-Lung-30m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l17|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 2.41e-04 | 193 | 70 | 4 | 64edc1d6fb0fe117767d494cf4a5723bf8be2804 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.41e-04 | 193 | 70 | 4 | fb28717fadd06c3840636d25409ce80c9254bd34 | |
| ToppCell | LA-14._Fibroblast_III|LA / Chamber and Cluster_Paper | 2.41e-04 | 193 | 70 | 4 | 7426c291bac59e539c427bcaae18abc7d397d44e | |
| ToppCell | nucseq-Epithelial-Epithelial_Alveolar-AT2|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.41e-04 | 193 | 70 | 4 | f3cc7cfdbc164a4ed42f87647111522b7d393bcb | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.41e-04 | 193 | 70 | 4 | 261cafc167c86ab277be4ea7f08b0173e2dde26e | |
| ToppCell | facs-Diaphragm-Limb_Muscle-3m-Mesenchymal-mesenchymal_stem_cell|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.41e-04 | 193 | 70 | 4 | 160691b671710be10220803d788c2c961c236af1 | |
| ToppCell | droplet-Limb_Muscle-nan-18m-Mesenchymal-mesenchymal_stem_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.41e-04 | 193 | 70 | 4 | 45b5cab4dfeb0ed3b13631db5963740a792b810f | |
| ToppCell | 10x5'v1-week_12-13-Hematopoietic-MK|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 2.46e-04 | 194 | 70 | 4 | 245a3eb6db9c862b73ad34a8cd2898a3688c16f6 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.46e-04 | 194 | 70 | 4 | 60622bd2f75bfe4c37f721cb12f03dab33f2f58d | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.46e-04 | 194 | 70 | 4 | 6e13549f697f7478b34fe71f7dd9d63c5d3db22e | |
| Disease | cholesteryl esters to total lipids in IDL percentage | 1.77e-04 | 50 | 64 | 3 | EFO_0022247 | |
| Disease | platelet component distribution width | 2.21e-04 | 755 | 64 | 8 | EFO_0007984 | |
| Disease | alcohol consumption measurement | VRK2 ANKRD20A5P DDR2 CACNA1I ADGRV1 ZNF90 PKD1L3 BANK1 CDH18 CCDC33 | 3.22e-04 | 1242 | 64 | 10 | EFO_0007878 |
| Disease | testosterone measurement | VRK2 DENND1B ANK2 PTPRG ADAMTS3 ANAPC1 ZNF629 TTC27 GPAM BANK1 | 3.96e-04 | 1275 | 64 | 10 | EFO_0004908 |
| Disease | erythritol measurement | 6.17e-04 | 17 | 64 | 2 | EFO_0021171 | |
| Disease | free cholesterol in large HDL measurement | 6.84e-04 | 79 | 64 | 3 | EFO_0022157 | |
| Disease | X-11470 measurement | 7.73e-04 | 19 | 64 | 2 | EFO_0021241 | |
| Disease | stroke, major depressive disorder | 7.73e-04 | 19 | 64 | 2 | EFO_0000712, MONDO_0002009 | |
| Disease | cognitive function measurement, self reported educational attainment | 1.04e-03 | 355 | 64 | 5 | EFO_0004784, EFO_0008354 | |
| Disease | unipolar depression | 1.13e-03 | 1206 | 64 | 9 | EFO_0003761 | |
| Disease | vital capacity | 1.34e-03 | 1236 | 64 | 9 | EFO_0004312 | |
| Disease | age at first sexual intercourse measurement | 1.46e-03 | 383 | 64 | 5 | EFO_0009749 | |
| Disease | cholesteryl esters:total lipids ratio, intermediate density lipoprotein measurement | 1.47e-03 | 103 | 64 | 3 | EFO_0008595, EFO_0020944 | |
| Disease | non-alcoholic fatty liver disease severity measurement | 1.69e-03 | 28 | 64 | 2 | EFO_0008421 | |
| Disease | functional brain measurement, language measurement | 1.69e-03 | 28 | 64 | 2 | EFO_0007797, EFO_0007849 | |
| Disease | brain connectivity measurement | 1.77e-03 | 400 | 64 | 5 | EFO_0005210 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| LPGKDSKHSDYINAN | 896 | P23470 | |
| EQRKGAGEKALYHAG | 101 | Q7Z4L5 | |
| EHGANPNLKDIYGNT | 121 | Q5TYW2 | |
| PGGKETAHNENKFYN | 746 | Q8NDB2 | |
| KHGANPNLKDIYGNT | 121 | Q5CZ79 | |
| GYQNDSPLHDAAKNG | 491 | Q99728 | |
| LPKGFCKNDGQHDAQ | 101 | Q8N5R6 | |
| EAAYPADGADAGQKH | 146 | Q7Z4R8 | |
| QSGHGKKKAAAYPAA | 46 | Q9UBJ2 | |
| EHGANPNLKDIYGNT | 121 | Q4UJ75 | |
| HTSAYGPDQRAQKKG | 16 | P41180 | |
| LDGGKAHGGNNNKYS | 231 | Q5VWW1 | |
| EHGANPNLKDIYGNT | 121 | A0PJZ0 | |
| QQINGHKFEGKEGDY | 5756 | Q8WXG9 | |
| ANPGIRDKQGYNAVH | 496 | O15084 | |
| GGDVKKDYGHIQSPN | 436 | P13497 | |
| GIDPYNAGSLKNHQE | 246 | Q01201 | |
| NYLEDKGLPHGNVSA | 636 | P52333 | |
| EHGANPNLKDIYGNT | 121 | Q5SQ80 | |
| NKPKHAELANEYAGF | 1161 | Q9H1A4 | |
| LEKGASPHATAKNGY | 616 | Q01484 | |
| KGALEQEAKYGQAPN | 246 | P55771 | |
| IIAAANPVGGHYNKA | 556 | Q9UJA3 | |
| NPVGGHYNKAKTVSE | 561 | Q9UJA3 | |
| HGKQVLDGNSNPYDI | 136 | Q16832 | |
| YKVDPEHLKENGGQK | 391 | Q9P2D0 | |
| NGHDLKYGTPELAAQ | 391 | Q8N448 | |
| EVNKVAGNFHFAPGK | 206 | Q9Y282 | |
| KHAAENPGKYNILGT | 516 | Q00839 | |
| KGPQGYGFNLHSDKS | 156 | Q15599 | |
| YIQAKDKGANPEGAH | 321 | Q9UN70 | |
| AHEKEFGSVNGDNKP | 396 | Q9H0B6 | |
| LAKEYHPDKNPNAGD | 31 | O60884 | |
| DGKEYHLAINKEPNS | 91 | Q96C23 | |
| EHGANPNLKDIYGNT | 121 | Q5VUR7 | |
| KNQATGHYILNGKGE | 756 | O15072 | |
| SQNHTGEPVGDDYKK | 56 | Q8N8J7 | |
| HAPGATDAFKKIGNA | 141 | Q8TBM8 | |
| DSNGKPADAVYGQKE | 46 | Q13283 | |
| ANPHKGAINFDNIGY | 331 | Q9P0X4 | |
| HPSSGEKLKYNQQGE | 226 | Q5VVM6 | |
| QVIQQFPGKDDHGYK | 511 | Q68D51 | |
| VSAKNQGAHDPDYEN | 26 | Q8IX19 | |
| HVNGDVKQGPISDNY | 621 | Q9Y2E5 | |
| PQYVGKLHSNSDKGD | 71 | Q13634 | |
| KHGATEYQQNKPPGK | 1196 | Q2VIQ3 | |
| PVYKLHNEKGGNSEK | 486 | Q6P3S1 | |
| LHYNDPKGNSSGNDK | 81 | Q8TAA1 | |
| GDDKHYGGFTNKQLQ | 1206 | P23468 | |
| KNPNTKHEEYGVGAS | 316 | Q8N328 | |
| RNGKTGQLHKAEGEY | 36 | Q9NUT2 | |
| KGHDNKGHSYNALPQ | 311 | Q14872 | |
| EGHYNGEQLGKPKKN | 361 | Q9HCL2 | |
| GYEESEGHNTPKLKN | 751 | Q8TE76 | |
| KHQDNKYPADVAANG | 91 | Q7Z443 | |
| AHNGDKPYVKNVGKL | 526 | Q8TBZ8 | |
| GTGPNVYHENDTIAK | 216 | Q4G0F5 | |
| KGDDVGKAANNPNHC | 181 | A6NNY8 | |
| YVPNANQADHDKDGK | 876 | P07996 | |
| LYTAKEAGGNPKQAA | 1776 | Q9Y490 | |
| DHFLVQYKNGDGQPK | 2331 | P22105 | |
| AGDHDYALPVGKQKQ | 301 | Q9NS37 | |
| VDAGNAYKKADPQEA | 86 | Q9H115 | |
| DTGELLGEYKGHKNQ | 221 | Q9BRX9 | |
| VKGSGHVQLKQGADY | 851 | Q9Y2K6 | |
| DEGKVHKRGYNGLNQ | 121 | Q03938 | |
| HIGENPYKNADGLIA | 591 | Q9UEG4 | |
| AHVYGNGQSEKPDEN | 716 | Q6P3X3 | |
| AKENNVDAVHPGYGF | 106 | P11498 | |
| IPYHKGNDKGDESQS | 156 | Q96GM8 | |
| NGNHKQYQENPRKGH | 196 | Q86Y07 | |
| KIKDEPDNAQEYSHG | 271 | Q5VZL5 |